<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="4635">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01227382</url>
  </required_header>
  <id_info>
    <org_study_id>SpyBite</org_study_id>
    <nct_id>NCT01227382</nct_id>
  </id_info>
  <brief_title>Accuracy of Spybite Forceps When Compared to Conventional Sampling Methods</brief_title>
  <official_title>Prospective Evaluation of the Accuracy of Spybite Biopsy Forceps for the Tissue Diagnosis of Lesion of the Pancreatobiliary System. ( Part of the &quot;The Clinical Utility of Cholangioscopy and Pancreatoscopy in the Diagnosis and Treatment of Pancreaticobiliary Disorders&quot; Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Florida</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Florida</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators are evaluating the use of a SpyBite biopsy forceps for tissue diagnosis
      when compared to standard biopsy techniques.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The participants will undergo an Endoscopic Retrograde Cholangiopancreatography (ERCP) with
      cholangiopancreatoscopy and evaluation of a bile duct or pancreatic duct stricture with
      three different types of techniques for biopsy: SpyBite biopsy forceps, cytology brush and
      RJ3biopsy forceps.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2006</start_date>
  <completion_date type="Actual">May 2015</completion_date>
  <primary_completion_date type="Actual">May 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label</study_design>
  <primary_outcome>
    <measure>Percentage of Participants With Accurate Diagnoses of Cancer</measure>
    <time_frame>up to 7 days after the procedure</time_frame>
    <safety_issue>No</safety_issue>
    <description>The diagnostic accuracy of the Spybite Biopsy forceps was compared to both the cytology brush and the RJ3 biopsy forceps sampling of any stricture or biliary lesions found on Endoscopic Retrograde Cholangiopancreatography (ERCP). All three methods were used at baseline to obtain a sample for the determination of cancer vs. no cancer.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Procedure Technical Success</measure>
    <time_frame>day 1</time_frame>
    <safety_issue>No</safety_issue>
    <description>The procedure technical success was defined when all of the following criteria were met: Successful advancement of the cholangioscope to the desired target, adequate cholangioscopic visualization of the area of interest, and successful applications of of all sampling maneuvers with visible tissue seen macroscopically when obtaining mini forceps and standard forceps biopsy samples.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Procedure Time</measure>
    <time_frame>120 minutes</time_frame>
    <safety_issue>No</safety_issue>
    <description>The total time to perform ERCP</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Cholangioscopy Time</measure>
    <time_frame>60 minutes</time_frame>
    <safety_issue>No</safety_issue>
    <description>This is the total time it takes for the dye to be performed during the ERCP.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cholangioscopy Visualization Time</measure>
    <time_frame>30 minutes</time_frame>
    <safety_issue>No</safety_issue>
    <description>The portion of the total ERCP time spent on Cholangioscopy visualization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sampling Times for Each Device</measure>
    <time_frame>15 minutes</time_frame>
    <safety_issue>No</safety_issue>
    <description>The sampling time of the Spybite Biopsy forceps was compared to both the cytology brush and the RJ3 biopsy forceps of any stricture or biliary lesions found on Endoscopic Retrograde Cholangiopancreatography (ERCP).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>24 hours</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Adverse events were prospectively evaluated at the end of the procedure, at discharge from the endoscopy unit, and by telephone call 24 hours post procedure. Adverse events were defined and graded using the 2010 American Society for Gastrointestinal Endoscopy consensus criteria.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">26</enrollment>
  <condition>Accuracy of Tissue Diagnosis</condition>
  <condition>Bile Duct Stricture</condition>
  <condition>Pancreatic Duct Stricture</condition>
  <arm_group>
    <arm_group_label>ERCP with Cholangiopancreatoscopy</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>The subjects who have been scheduled for an Endoscopic Retrograde Cholangiopancreatography (ERCP) with Cholangiopancreatoscopy for evaluation of a bile duct or pancreatic duct stricture sampling.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>ERCP with cholangiopancreatoscopy</intervention_name>
    <description>Endoscopic Retrograde Cholangiopancreatography (ERCP)with cholangiopancreatoscopy and sampling of stricture with SpyBite biopsy forceps, cytology brush and RJ3biopsy forceps</description>
    <arm_group_label>ERCP with Cholangiopancreatoscopy</arm_group_label>
    <other_name>Endoscopic Retrograde Cholangiopancreatography</other_name>
    <other_name>ERCP</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subjects is 18 years or older

          2. Scheduled to undergo Endoscopic Retrograde Cholangiopancreatography (ERCP) wiht
             cholangioscopy and/or pancreatoscopy at the University of Florida Gainesville Florida
             as medically indicated.

          3. Lesion of the pancreatobiliary system that requires tissue sampling as medically
             indicated

          4. Subject myst be able to give informed consent

        Exclusion Criteria:

          1. Any contraindication to Endoscopic Retrograde Cholangiopancreatography (ERCP)

          2. The subject is unable to give informed consent
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter Draganov, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Flordia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Shands at UF Ensopcopy</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2015</verification_date>
  <lastchanged_date>July 29, 2015</lastchanged_date>
  <firstreceived_date>October 18, 2010</firstreceived_date>
  <firstreceived_results_date>June 29, 2015</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Constriction, Pathologic</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Indeterminate Biliary Lesions Requiring Tissue Sampling</title>
          <description>Each patient underwent triple sampling of the identified biliary lesion with cholangioscopy-guided mini-forceps biopsy, standard cytology brushing, and standard forceps biopsy.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Indeterminate Biliary Lesions Requiring Tissue Sampling</title>
          <description>Each patient underwent triple sampling of the identified biliary lesion with cholangioscopy-guided mini-forceps biopsy, standard cytology brushing, and standard forceps biopsy.</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="26"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="67.92" spread="13.37"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="11"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="15"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>United States</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="26"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Accurate Diagnoses of Cancer</title>
        <description>The diagnostic accuracy of the Spybite Biopsy forceps was compared to both the cytology brush and the RJ3 biopsy forceps sampling of any stricture or biliary lesions found on Endoscopic Retrograde Cholangiopancreatography (ERCP). All three methods were used at baseline to obtain a sample for the determination of cancer vs. no cancer.</description>
        <time_frame>up to 7 days after the procedure</time_frame>
        <safety_issue>No</safety_issue>
        <population>Percentage of participants with accurate diagnoses of cancer</population>
        <group_list>
          <group group_id="O1">
            <title>Diagnostic Accuracy of SpyBite Biopsy Forceps Compared to the</title>
            <description>Each patient underwent triple sampling of the identified biliary lesion or stricture with cholangioscopy-guided Spybite forceps biopsy, standard cytology brushing, and standard forceps biopsy.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="26"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Percentage of Participants With Accurate Diagnoses of Cancer</title>
            <description>The diagnostic accuracy of the Spybite Biopsy forceps was compared to both the cytology brush and the RJ3 biopsy forceps sampling of any stricture or biliary lesions found on Endoscopic Retrograde Cholangiopancreatography (ERCP). All three methods were used at baseline to obtain a sample for the determination of cancer vs. no cancer.</description>
            <units>percentage of accurate diagnoses</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Cytology brush</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="38.5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Standard forceps biopsy</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="53.9"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Spybite biopsy</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="84.6"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Procedure Technical Success</title>
        <description>The procedure technical success was defined when all of the following criteria were met: Successful advancement of the cholangioscope to the desired target, adequate cholangioscopic visualization of the area of interest, and successful applications of of all sampling maneuvers with visible tissue seen macroscopically when obtaining mini forceps and standard forceps biopsy samples.</description>
        <time_frame>day 1</time_frame>
        <safety_issue>No</safety_issue>
        <population>Percentage of participants with accurate diagnoses of cancer</population>
        <group_list>
          <group group_id="O1">
            <title>Indeterminate Biliary Lesions Requiring Tissue Sampling</title>
            <description>Each patient underwent triple sampling of the identified biliary lesion with cholangioscopy-guided mini-forceps biopsy, standard cytology brushing, and standard forceps biopsy.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="26"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Procedure Technical Success</title>
            <description>The procedure technical success was defined when all of the following criteria were met: Successful advancement of the cholangioscope to the desired target, adequate cholangioscopic visualization of the area of interest, and successful applications of of all sampling maneuvers with visible tissue seen macroscopically when obtaining mini forceps and standard forceps biopsy samples.</description>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="26"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Procedure Time</title>
        <description>The total time to perform ERCP</description>
        <time_frame>120 minutes</time_frame>
        <safety_issue>No</safety_issue>
        <population>Percentage of participants with accurate diagnoses of cancer</population>
        <group_list>
          <group group_id="O1">
            <title>Indeterminate Biliary Lesions Requiring Tissue Sampling</title>
            <description>Each patient underwent triple sampling of the identified biliary lesion or stricture with cholangioscopy-guided Spybite forceps biopsy, standard cytology brushing, and standard forceps biopsy.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="26"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Total Procedure Time</title>
            <description>The total time to perform ERCP</description>
            <units>minutes</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="54.00" spread="12.71"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Cholangioscopy Time</title>
        <description>This is the total time it takes for the dye to be performed during the ERCP.</description>
        <time_frame>60 minutes</time_frame>
        <safety_issue>No</safety_issue>
        <population>Percentage of participants with accurate diagnoses of cancer</population>
        <group_list>
          <group group_id="O1">
            <title>Indeterminate Biliary Lesions Requiring Tissue Sampling</title>
            <description>Each patient underwent triple sampling of the identified biliary lesion or stricture with cholangioscopy-guided Spybite forceps biopsy, standard cytology brushing, and standard forceps biopsy.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="26"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Total Cholangioscopy Time</title>
            <description>This is the total time it takes for the dye to be performed during the ERCP.</description>
            <units>minutes</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="23.65" spread="9.43"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cholangioscopy Visualization Time</title>
        <description>The portion of the total ERCP time spent on Cholangioscopy visualization.</description>
        <time_frame>30 minutes</time_frame>
        <safety_issue>No</safety_issue>
        <population>Percentage of participants with accurate diagnoses of cancer</population>
        <group_list>
          <group group_id="O1">
            <title>Indeterminate Biliary Lesions Requiring Tissue Sampling</title>
            <description>Each patient underwent triple sampling of the identified biliary lesion with cholangioscopy-guided mini-forceps biopsy, standard cytology brushing, and standard forceps biopsy.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="26"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Cholangioscopy Visualization Time</title>
            <description>The portion of the total ERCP time spent on Cholangioscopy visualization.</description>
            <units>minutes</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="11.69" spread="8.03"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Sampling Times for Each Device</title>
        <description>The sampling time of the Spybite Biopsy forceps was compared to both the cytology brush and the RJ3 biopsy forceps of any stricture or biliary lesions found on Endoscopic Retrograde Cholangiopancreatography (ERCP).</description>
        <time_frame>15 minutes</time_frame>
        <safety_issue>No</safety_issue>
        <population>Percentage of participants with accurate diagnoses of cancer</population>
        <group_list>
          <group group_id="O1">
            <title>Indeterminate Biliary Lesions Requiring Tissue Sampling</title>
            <description>Each patient underwent triple sampling of the identified biliary lesion or stricture with cholangioscopy-guided Spybite forceps biopsy, standard cytology brushing, and standard forceps biopsy.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="26"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Sampling Times for Each Device</title>
            <description>The sampling time of the Spybite Biopsy forceps was compared to both the cytology brush and the RJ3 biopsy forceps of any stricture or biliary lesions found on Endoscopic Retrograde Cholangiopancreatography (ERCP).</description>
            <units>minutes</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <sub_title>Spybite forceps</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="11.92" spread="4.67"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Standard cytology brushing</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3.77" spread="1.21"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Standard forceps biopsy</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="5.73" spread="3.11"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adverse Events</title>
        <description>Adverse events were prospectively evaluated at the end of the procedure, at discharge from the endoscopy unit, and by telephone call 24 hours post procedure. Adverse events were defined and graded using the 2010 American Society for Gastrointestinal Endoscopy consensus criteria.</description>
        <time_frame>24 hours</time_frame>
        <safety_issue>Yes</safety_issue>
        <population>Percentage of participants with accurate diagnoses of cancer</population>
        <group_list>
          <group group_id="O1">
            <title>Indeterminate Biliary Lesions Requiring Tissue Sampling</title>
            <description>Each patient underwent triple sampling of the identified biliary lesion with cholangioscopy-guided mini-forceps biopsy, standard cytology brushing, and standard forceps biopsy.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="26"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Adverse Events</title>
            <description>Adverse events were prospectively evaluated at the end of the procedure, at discharge from the endoscopy unit, and by telephone call 24 hours post procedure. Adverse events were defined and graded using the 2010 American Society for Gastrointestinal Endoscopy consensus criteria.</description>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="3"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>2 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Indeterminate Biliary Lesions Requiring Tissue Sampling</title>
          <description>Each patient underwent triple sampling of the identified biliary lesion or stricture with cholangioscopy-guided Spybite forceps biopsy, standard cytology brushing, and standard forceps biopsy.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (10.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Postsphincterotomy Bleeding</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (10.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Mild Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Peter V. Draganov</name_or_title>
      <organization>University of Florida</organization>
      <phone>(352) 273-9472</phone>
      <email>Peter.Draganov@medicine.ufl.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
